DAPT Stays Helpful for Minor Stroke Even With Later Presentation, Worse Symptoms
The benefit of dual antiplatelet therapy (DAPT) for a minor ischemic stroke seems to apply outside the 24-hour time window and minimal stroke symptoms for which the treatment is currently recommended, based on results from the INSPIRES trial. Administered within 72 hours after onset of mild ischemic stroke or high-risk transient ischemic attack (TIA), the […]
Dual Antiplatelet Therapy Proves Mettle in Minor Stroke
DALLAS — Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute minor stroke who presented within 4.5 hours of onset, and had no “clearly disabling deficit,” functional outcome was similar between the two methods, according to Thanh […]
Early DAPT Improves Outcomes for Strokes With No Other Tx Options
DALLAS — Adding tirofiban (Aggrastat) to aspirin for dual antiplatelet therapy (DAPT) within 24 hours of acute ischemic stroke improved outcomes for patients who weren’t candidates for thrombolytic or endovascular treatment, according to a phase III trial from China. The combination of the glycoprotein IIb/IIIa inhibitor with aspirin shifted modified Rankin Scale (mRS) scores in […]
Triplet in First-Line Kidney Cancer Thwarts Disease Progression
PARIS — Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), the phase III COSMIC-313 trial found. Among 550 patients with untreated intermediate- or poor-risk disease, those treated with the triplet therapy had a median PFS that was not […]
Dual Bronchodilators No Help for Symptomatic Smokers With Preserved Lung Function
Inhaled dual bronchodilator therapy did not decrease respiratory symptoms in former or current smokers with preserved lung function, the RETHINC trial showed. Among 535 symptomatic smokers with a 10 pack-year history and preserved lung function assessed by spirometry, 56.4% in the treatment group and 59.0% in the placebo group had a least a 4-point decrease […]
Short DAPT Just as Good for High-Bleeding Risk Stenting After MI
For high-bleeding risk patients, a shorter duration of dual antiplatelet therapy (DAPT) appeared just as safe for those getting novel stent after acute myocardial infarction (MI) in the MASTER-DAPT trial. Stopping anticoagulant at 30 days didn’t yield significantly different outcomes whether patients had a prior MI or not, reported Pieter C. Smits, MD, PhD, of […]
One Month of DAPT Reasonable in Patients at High Bleeding Risk
Dual antiplatelet therapy (DAPT) for 1 month after percutaneous coronary intervention (PCI) lowered bleeding rates and was non-inferior for ischemic events compared with 3-month DAPT in patients at high bleeding risk, according to results of the MASTER DAPT trial. Among the 4,579 patients in the intention-to-treat (ITT) population, major or clinically relevant non-major bleeding occurred […]